Market closed
Landec/$LFCR
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Landec
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that offers differentiated capabilities in the development, filling, and finishing of complex sterile injectable pharmaceutical products in syringes and vials. It manufactures injectable-grade Hyaluronic Acid. Lifecore recognizes revenue in two different product categories, CDMO and fermentation.
Ticker
$LFCR
Sector
Trading on
Industry
Life Sciences Tools & Services
Headquarters
Employees
524
Website
Landec Metrics
BasicAdvanced
$207M
-
-$0.53
0.99
-
Price and volume
Market cap
$207M
Beta
0.99
52-week high
$8.45
52-week low
$3.68
Average daily volume
148K
Financial strength
Current ratio
2.32
Quick ratio
1.127
Long term debt to equity
211.598
Total debt to equity
219.779
Interest coverage (TTM)
-0.47%
Management effectiveness
Return on assets (TTM)
-2.47%
Return on equity (TTM)
-29.58%
Valuation
Price to revenue (TTM)
1.351
Price to book
13.4
Price to tangible book (TTM)
-78.68
Price to free cash flow (TTM)
-12.277
Growth
Revenue change (TTM)
16.47%
Earnings per share change (TTM)
-77.93%
3-year revenue growth (CAGR)
-2.77%
3-year earnings per share growth (CAGR)
-35.08%
What the Analysts think about Landec
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Landec stock.
Landec Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Landec Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Landec News
AllArticlesVideos
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Lifecore Biomedical, Inc. (LFCR) and Encourages Shareholders to Learn More About the Investigation
Accesswire·2 weeks ago
Lifecore Biomedical, Inc. (LFCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
Accesswire·2 weeks ago
Lifecore Biomedical, Inc. (LFCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
Accesswire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Landec stock?
Landec (LFCR) has a market cap of $207M as of February 25, 2025.
What is the P/E ratio for Landec stock?
The price to earnings (P/E) ratio for Landec (LFCR) stock is 0 as of February 25, 2025.
Does Landec stock pay dividends?
No, Landec (LFCR) stock does not pay dividends to its shareholders as of February 25, 2025.
When is the next Landec dividend payment date?
Landec (LFCR) stock does not pay dividends to its shareholders.
What is the beta indicator for Landec?
Landec (LFCR) has a beta rating of 0.99. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.